Photocure ASA (PHCUF)

OTCMKTS · Delayed Price · Currency is USD
4.320
-0.853 (-16.49%)
At close: Mar 11, 2025
-27.39%
Market Cap 138.60M
Revenue (ttm) 46.25M
Net Income (ttm) -293.99K
Shares Out n/a
EPS (ttm) -0.01
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 953
Average Volume 1,089
Open 4.320
Previous Close 5.173
Day's Range 4.320 - 4.320
52-Week Range 4.320 - 5.950
Beta 0.71
RSI 38.85
Earnings Date Apr 11, 2025

About Photocure ASA

Photocure ASA, together with its subsidiaries, engages in the research, development, production, distribution, marketing, and sale of pharmaceutical products. It operates through Commercial Franchise and Development Portfolio segments. The company offers Hexvix/Cysview for the detection and management of bladder cancer. It also develops Cevira for the treatment of human papilloma virus-induced cervical precancerous lesions. The company has a license agreement with Asieris MediTech Co to develop and commercialize Cevira; and a strategic agreemen... [Read more]

Sector Healthcare
Founded 1993
Employees 102
Stock Exchange OTCMKTS
Ticker Symbol PHCUF
Full Company Profile

Financial Performance

Financial numbers in NOK Financial Statements

News

Photocure ASA: Results for the fourth quarter of 2024

OSLO, Norway , Feb. 19, 2025 /PRNewswire/ -- Photocure ASA (OSE:PHO) today reported Hexvix®/Cysview® revenues of NOK 128.6 million in the fourth quarter of 2024 (Q4 2023: NOK 114.2 million) and EBITDA...

2 months ago - PRNewsWire

Photocure ASA: Results for the third quarter of 2024

OSLO, Norway , Nov. 13, 2024 /PRNewswire/ -- Photocure ASA (OSE: PHO) today reported Hexvix®/Cysview® revenues of NOK 120.1 million in the third quarter of 2024 (Q3 2023: NOK 107.3 million), and  EBIT...

5 months ago - PRNewsWire

Photocure ASA: Results for the second quarter of 2024

OSLO, Norway , Aug. 7, 2024 /PRNewswire/ -- Photocure ASA (OSE: PHO), The Bladder Cancer Company, today reported Hexvix ® /Cysview ®  revenues of NOK 122.4 million in the second quarter of 2024 (Q2 20...

9 months ago - PRNewsWire